T1506 |
Vidarabine
|
5536-17-4
|
99.91%
|
|
Vidarabine is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA ...
|
T3061 |
Lorlatinib
|
1454846-35-5
|
99.93%
|
|
PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), wit...
|
T1829 |
Ruxolitinib
|
941678-49-5
|
99.93%
|
|
Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50: 3.3/2.8 nM) and is relatively less selective for JAK3 (IC50: 322 nM).
|
T1936 |
Alectinib
|
1256580-46-7
|
99.97%
|
|
CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
|
T6790 |
BMS-911543
|
1271022-90-2
|
99.98%
|
|
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.
|
T15096 |
Delgocitinib
|
1263774-59-9
|
98%
|
|
Delgocitinib is a novel and specific inhibitor of JAK (IC50s: 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2).
|
T5049 |
NVP-BSK805
|
1092499-93-8
|
98%
|
|
NVP-BSK805 is an ATP-competitive JAK2 inhibitor.
|
T17184 |
Tyrosine kinase inhibitor
|
1021950-26-4
|
|
|
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
|
T6933 |
Peficitinib
|
944118-01-8
|
|
|
Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
|